Bupropion
NIDA-17566-1
Phase 2 small_molecule completed
Quick answer
Bupropion for Schizophrenia and Disorders With Psychotic Features is a Phase 2 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BRIGHT MINDS BIOSCIENCES INC.
- Indication
- Schizophrenia and Disorders With Psychotic Features
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed